Skip to main content
Delfa

← Trials/Trial dossier/NCT04629495

REACH

Active not recruitingPhase 2

Rapamycin - Effects on Alzheimer's and Cognitive Health

Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)

Asset

Sirolimus

Listed sites

1

Recruiting sites

-

Enrollment

40

actual

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criteria

Alzheimer's diseaseMMSE 18-30AD symptomatic therapy: stable

Primary endpoints

Number of adverse eventsGlucose levelAlbumin

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDHSC20200763H
NCT IDNCT04629495

Timeline

Milestones

Study first posted2020-11-16actual
Study start2021-08-11actual
Primary completion2026-03-05actual
Last update posted2026-06-09actual
Study completion2027-03-05estimated

Assets

Drug assets

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age55 Years
Maximum age89 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Both genders and all ethnic groups

2. Ages 55 to 89 years

3. Diagnosis of MCI or AD (Mini Mental Status Examination (MMSE): 18-30; Clinical Dementia Rating Scale (CDR) = 0.5 - 1; California Verbal Learning Test III (CVLT-III) Delayed Recall ≤16% based on age-adjusted norms, clinician approval)

4. Amyloid positivity based on Amyloid PET Imaging

5. Labs: Normal blood cell counts without clinically significant excursions; normal liver and renal function; and glucose control (HbA1c < 6.5%). Fasting lipid panel and prothrombin time/prothrombin time test/international normalized ration (PT/PTT/INR) within normal limits

6. A legally authorized representative (LAR) designated to sign informed consent (if necessary) must attend the Screening visit and accompany the participant to all remaining visits to provide reported outcomes

7. Stable dose of AD medications (Donepezil, rivastigmine, Memantine, galantamine) for at least three months is allowed

Exclusion criteria

1. Diabetes (HBA1c≥6.5% or antidiabetic medications)

2. History of skin ulcers or poor wound healing

3. Current tobacco or illicit drug use or alcohol abuse

4. Use of anti-platelet or anti-coagulant medications other than aspirin

5. Current medications that affect cytochrome 450 3A4 (CYP3A4)

6. Immunosuppressant therapy within the last year

7. Chemotherapy or radiation treatment within the last year

8. Current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities

9. Untreated hypertriglyceridemia (fasting triglycerides < 250 mg/dl)

10. Current or chronic history of pulmonary disease or abnormal pulse oximetry (<90%)

11. Chronic heart failure

12. Pregnancy or lactation

13. Recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack

14. Significant neurological conditions other than AD or MCI

15. Poorly controlled blood pressure (systolic BP>160, diastolic BP>90 mmHg - based on two readings)

16. Active inflammatory, COVID-19, autoimmune, infectious, hepatic, gastrointestinal, malignant, and/or severe mental illness

17. History of, or MRI, or CT positive for, any space occupying lesion, including mass effect or abnormal intracranial pressure, which would indicate contraindications to lumbar puncture

18. Organ transplant recipients

Endpoints (15)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
5
Global cognition
2
Neuroimaging
2
Other clinical outcomes
2
Function / daily living
1
Behavior / neuropsychiatric
1
Amyloid biomarkers
1
Safety / tolerability / PK
1

Global cognition

2 endpoints
Secondary/protocol endpoint

Change in Cognition using preclinical Alzheimer's Cognitive Composite 5 (PACC5)

Time frame:Baseline to 12 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Cognition using Clinical Dementia Rating Scale sum of Boxes (CDR-SOB)

Time frame:Baseline to 12 months

Clinical Dementia Rating-Sum of Boxes (CDR-SB)

change from baseline, improvement

Function / daily living

1 endpoint
Secondary/protocol endpoint

Change in Functional status

Time frame:Baseline to 12 months

change from baseline, improvement

Behavior / neuropsychiatric

1 endpoint
Secondary/protocol endpoint

Change in Neuropsychiatric symptoms

Time frame:Baseline to 12 months

change from baseline, improvement

Amyloid biomarkers

1 endpoint
Secondary/protocol endpoint

Change in CSF amyloid beta

Time frame:Baseline to 12 months

change from baseline, improvement

Neuroimaging

2 endpoints
Secondary/protocol endpoint

Change in cerebral glucose metabolism

Time frame:Baseline to 12 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Brain Volumetry

Time frame:Baseline to 12 months

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Number of adverse events

Time frame:Baseline to 12 months

event count, event

Other clinical outcomes

2 endpoints
Secondary/protocol endpoint

Change in Gait Speed

Time frame:Baseline to 12 months

change from baseline, improvement

Secondary/protocol endpoint

Change in Grip Strength

Time frame:Baseline to 12 months

change from baseline, improvement

Other (unclassified)

5 endpoints
Primary/protocol endpoint/low confidence

Change in glucose level

Time frame:Baseline to 12 months

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in albumin

Time frame:Baseline to 12 months

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in carbon dioxide or bicarbonate (CO2)

Time frame:Baseline to 12 months

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in calcium

Time frame:Baseline to 12 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Central nervous system penetration of rapamycin

Time frame:Baseline and 12 months

ratio, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.